Glutamate: The Missing Piece in Treatment Prediction
The laboratory’s most significant contribution centers on discoveries about glutamate dysfunction in early psychosis. Through sophisticated MRI spectroscopy techniques applied to antipsychotic-naïve patients, Dr. de la Fuente-Sandoval’s team identified elevated glutamate levels specifically within the associative striatum. More importantly, they demonstrated that these elevations normalize following effective antipsychotic treatment.
This finding opens unprecedented possibilities for treatment personalization. Rather than subjecting patients to potentially ineffective medications for weeks or months, clinicians might soon predict treatment response through baseline neuroimaging assessments. What implications might this hold for reducing the duration of untreated psychosis, a factor strongly associated with long-term outcomes? The potential to match patients with optimal treatments from the outset represents a paradigm shift in psychiatric care delivery